Compare Dollar General Corp. (DG) vs State Street SPDR S&P Biotech ETF (XBI) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Dollar General Corp. vs State Street SPDR S&P Biotech ETF — how do they compare? Dollar General Corp. trades at $127.32 (market cap $27.42B), while State Street SPDR S&P Biotech ETF trades at $153.75 (market cap $10.11B). The key difference: Dollar General Corp. is far larger — about 2.7× State Street SPDR S&P Biotech ETF's market cap, and Dollar General Corp. pays a 1.9% dividend while State Street SPDR S&P Biotech ETF pays none. Which is the better fit depends on your goals — on Pluang, investors hold Dollar General Corp. for 59 Days and State Street SPDR S&P Biotech ETF for 38 Days on average.
| DG | XBI | |
|---|---|---|
Market Cap | $27.42B | $10.11B |
Volume | 2,291,517 | 12,903,266 |
Sector | Consumer Staples | Broad Market / Factor |
52-Week High | $156.26 | $169.55 |
52-Week Low | $95.94 | $104.99 |
Typical Hold Time | 59 Days | 38 Days |
Enterprise Value | $41.60B | — |
Dividend Yield | 1.9% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Dollar General (DG) trades at $126.16, up 3.27% on the day, with a bullish technical signal and strong earnings beats in recent quarters. The stock shows solid fundamentals with a P/E of 16.14 and ROE of 19.69%, supported by positive cash flow trends and a growing revenue base. Recent news highlights strategic initiatives like tariff refunds, delivery expansion with Instacart, and the DG Media Network, enhancing its value-retail positioning.
The outlook for DG is positive, driven by earnings momentum and analyst consensus pointing to a $137.27 price target. Key opportunities include margin expansion from cost initiatives and digital growth, while risks involve competitive pressures and consumer spending sensitivity. The stock presents a compelling case for value investors seeking steady growth in the discount retail sector.
XBI trades at $153.84, up 2.4% today, but technical indicators signal a bearish trend with resistance at $154. The ETF's modified equal-weight structure offers broad biotech exposure, benefiting from M&A activity and positive clinical catalysts, though key financial ratios are unavailable. Recent news highlights sector optimism driven by cancer vaccine breakthroughs and improved capital access.
Outlook is mixed: bullish sentiment from innovation and M&A supports growth potential, but high volatility and expense ratios relative to peers pose risks. Analyst consensus is neutral (100% Hold), suggesting cautious optimism amid technical bearishness.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Dollar General Corp.
A leading American discount retailer, Dollar General operates over 18,000 stores in 47 states, selling branded and private-label products across a wide variety of categories. In fiscal 2021, 77% of net sales came from consumables (including paper and cleaning products, packaged and perishable food, tobacco, and health and beauty items), 12% from seasonal merchandise (such as toys, greeting cards, decorations, and gardening supplies), 7% from home products (for example, kitchen supplies, small appliances, and cookware), and 4% from basic apparel. Stores average roughly 7,400 square feet, and about 75% of Dollar General locations are in towns of 20,000 or fewer people. The firm emphasizes value, with most of its items sold at everyday low prices of $5 or less.
Read more on DG →About State Street SPDR S&P Biotech ETF
XBI is an equal-weighted ETF that tracks the U.S. biotechnology segment. It provides diversified exposure to small, mid, and large-cap biotech firms involved in drug discovery and medical research, such as Moderna and Exact Sciences.
Read more on XBI →
